# A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis

> **NCT06630559** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Celltrion** · enrollment: 153 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **BIOLOGICAL:** CT-P55
- **BIOLOGICAL:** EU-approved Cosentyx

## Key facts

- **NCT ID:** NCT06630559
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-05-26
- **Primary completion:** 2026-02-18
- **Final completion:** 2026-10
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06630559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06630559, "A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06630559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*